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http:WHAT THIS PAPER ADDS
The study is an evaluation of the ﬁrst (and largest) patient cohort, treated with a new technique called the
“Covered Endovascular Reconstruction of the Aortic Bifurcation,” the CERAB technique. The study shows the
safety and excellent patency of this technique when treating aortoiliac arterial occlusive disease. These ﬁrst
promising results are an indicator for a potential shift from open surgical bypass grafting to endovascular
treatment for patients suffering from disabling intermittent claudication or critical limb ischemia.Objective: In this study the ﬁrst results are presented of a new endovascular technique using covered stents to
reconstruct the aortic bifurcation in patients with aortoiliac occlusive disease. With the “Covered Endovascular
Reconstruction of the Aortic Bifurcation” (CERAB) technique, the anatomy and physiology of the aortic
bifurcation is mimicked.
Material and methods: Between 2009 and March 2014, 103 patients (51 male, 52 female) suffering from
obstructive lesions at the level of the aortic bifurcation were treated with CERAB in two clinics. The median age
was 61 years (range 36e85 years). Lesion morphology was evaluated by CT angiography. Six TASC-II B lesions,
nine TASC-II C lesions, and 88 TASC-II D lesions were treated. Follow up was a median 12 months (range 0e49
months) and consisted of clinical examination, ankle brachial indices, and duplex ultrasound examination.
Results: Technical success was obtained in 98 procedures (95.1%). In ﬁve cases lesions could not be recanalized.
Primary patency was 87.3% at 1 year and 82.3% at 2 years, while secondary patency was 95.0% at 1 year and
95.0% at 2 years. Mean ankle brachial indices improved signiﬁcantly from 0.64  0.21 before to 0.91  014, after
the procedure (p < .001). The overall 30 day complication rate was 23.3%, including 22 minor complications and
two major complications (1.9%). There was no 30 day mortality. Median hospital stay was 2 days (range 1e16
days).
Conclusions: The CERAB technique appears to be a safe and feasible alternative to open surgical reconstruction
of the aortic bifurcation in complex occlusive disease. Comparative studies with the current gold standards are
indicated.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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According to the Trans-Atlantic Inter-society Consensus
document (TASC-II), surgical reconstruction, typically by
means of aorto-bi-iliac bypass grafting, is the treatment of
choice for extensive aortoiliac occlusive lesions, classiﬁed as
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//dx.doi.org/10.1016/j.ejvs.2015.06.112occlusion of the common iliac arteries (TASC-II C). This is the
consequence of the good long-term patency rates after
surgical reconstruction. Surgery, however, is associated with
both early and late morbidity and peri-operative mortality.
Therefore, comorbidities should be taken into consideration
when planning a reconstruction for aortoiliac occlusive
disease (AIOD).1
In 1991 the kissing stent technique was introduced as an
endovascular treatment alternative for bilateral aortoiliac
occlusive disease. In this technique, two stents are placed
simultaneously in the common iliac arteries, with an over-
lap in the distal aorta.2,3 Reported technical success rates
varied between 89% and 100% with a 1 year primary
patency rate between 76% and 98% with the use of bare
First Results of the CERAB Technique 639metal stents (BMS) in TASC-II C and D lesions.4 Variations in
patient and lesion characteristics and techniques used may
have caused the variation in outcome.
Covered stents may increase patency rates in extensive
disease, as shown by the COBEST trial and conﬁrmed in
various case series.5e9 The COBEST trial showed that
covered balloon expandable stents (CBES) have a superior
primary patency rate and clinical improvement outcome at
24 months when compared with bare metal stents.9 In
addition CBES may immediately treat or reduce the risk of
procedural complications such as dissection, perforation,
and embolization, with potential for reducing morbidity and
mortality.
The Covered Endovascular Reconstruction of the Aortic
Bifurcation (CERAB) technique was developed in an
attempt to overcome the anatomical and physiological
disadvantages of kissing stents.10 Patency rates of kissing
stents may be inﬂuenced by geometrical factors such as
radial mismatch, deﬁned as the perfused dead lumen
space around the stents, protrusion mismatch deﬁned as
the overlap distance of the stents in the distal aorta, and
stent conformation. All these factors may cause ﬂow dis-
turbances leading to re-circulation, turbulence, and stasis
of blood, which in turn, may cause thrombus formation
and intimal neohyperplasia.11e14 A recent in vitro
geometrical study showed superior stent conformation and
lower radial mismatch in the CERAB conﬁguration when
compared with the kissing stent conﬁguration.15 In the
present study the ﬁrst clinical results of the CERAB tech-
nique are presented.
METHODS
Patients
Consecutive patients treated between February 2009 and
March 2014 using the CERAB technique were prospectively
gathered in a database and retrospectively analyzed.
Permission was obtained from the institutional review
board.
Patients were treated in two hospitals: Rijnstate Hospital
Arnhem, the Netherlands and ZNA Clinics, Antwerp,
Belgium. Patients with acute limb ischemia were excluded
from this analysis, as were patients treated with chimney
conﬁgurations. Anatomical suitability for the CERAB proce-
dure was assessed using computed tomography (CT) angi-
ography. In all patients cardiovascular risk reduction was
performed, including prescription of anti-platelet therapy
(in the absence of anti-coagulant therapy) and statins if
indicated. All patients treated for intermittent claudication
were initially treated with (supervised) walking exercise and
considered for treatment only if symptoms persisted and
were disabling.
Demographics, clinical status, medical history, and pro-
cedural aspects were noted. The clinical status was assessed
using the Rutherford Classiﬁcation for chronic ischemia.16
Comorbidity was scored according to the Society for
Vascular Surgery and American Association for Vascular
Surgery medical comorbidity scoring system.17CT images were reviewed and scored according to the
TASC-II criteria.1 Routine follow up included clinical
assessment, ankle brachial index (ABI) measurements, and
duplex ultrasound scans at 1, 3, 6, and 12 months, and
annually thereafter. Complications and additional treat-
ments were registered in the hospital ﬁles.
Technique
Details of the CERAB technique have been described pre-
viously.10 Brieﬂy, patients were treated either in a hybrid
operating theater or in a catheterization laboratory. Two
introducer sheaths were introduced (9Fr and 7Fr) into the
common femoral arteries, either percutaneously or by
surgical cut down. Heparin (5,000 units) was administered
to all patients. The occlusive lesion was then passed, either
subintimal or endoluminal, using regular catheters (Super
Torque, Cordis Corporation, Miami Lakes, FL) and a Terumo
wire (Terumo Medical Corporation, Elkton, MD). After
gaining re-entry into the lumen of the aorta, angiography
conﬁrmed proper positioning for those with a subintimal
passage (Fig. 1A). A 12 mm V12 LD balloon expandable
ePTFE covered stent (Atrium Medical, Maquet Getinge
Group, Hudson, NH) was expanded in the distal aorta
approximately 20 mm above the bifurcation through the 9
Fr sheath. The proximal 2/3 part of the aortic stent was
ﬂared with a larger balloon, usually 16 mm, thereby creating
a funnel shaped covered stent. Subsequently, two covered
CBES were placed proximally in the distal 1/3 of the aortic
stent (consequently the part of the covered stent that was
still 12 mm in diameter) and distally into the common iliac
arteries and were deployed simultaneously (Fig. 1B). Typi-
cally, two V12 balloon expandable ePTFE covered stents
(Atrium Medical, Maquet Getinge Group, Hudson, NH) with
a diameter of 8 mm were used, with these two stents
creating a tight connection with the ﬁrst aortic stent,
thereby creating the new aortic bifurcation (Fig. 1C). When
required, distal extensions were added. The sheaths were
removed from the common femoral artery and the punc-
ture sites were closed, usually using a closure device (Angio-
Seal, St. Jude Medical, St. Paul, MN or Perclose/Starclose,
Abbott Vascular, Abbott Park, IL) or sutured in cases of open
introduction. Concomitant endarterectomy of the femoral
artery or external iliac artery was performed in cases of
multilevel disease. Patients received standard statin treat-
ment and dual anti-platelets for 6 months followed by
mono-therapy, unless oral anti-coagulation was indicated
for other reasons.
Deﬁnitions
The primary outcome measure was 1 year primary patency.
Secondary outcomes were technical success, length of
hospital stay, morbidity, mortality, clinical improvement,
secondary patency, and limb salvage.
Classiﬁcations were used according to the reporting
standards.16,18 Technical success was deﬁned as stent
placement restoring blood ﬂow with <30% residual steno-
sis. Primary patency was deﬁned as uninterrupted patency
Figure 1. (A) Angiography of a 52 year old female patient with disabling intermittent claudication showing total occlusion of the distal
aorta and both iliac arteries. (B) Both iliac stents are simultaneously deployed, with 2 cm overlap into the funnel shaped aortic stent,
thereby creating a tight connection. (C) Control angiography showing the CERAB conﬁguration in place, thereby creating a new aortic
bifurcation.
640 F.A.B. Grimme et al.in the absence of re-stenosis or occlusion, without any
procedures performed on the vessel or stent. Secondary
patency was deﬁned as patency achieved by all procedures
aimed at recanalizing an occluded CBES, thereby preserving
the endograft. Freedom from target lesion revascularization
(TLR) was deﬁned as an open endograft without procedures
performed for re-stenosis or occlusion leading to symptoms
requiring an intervention. Criteria for re-intervention
included clinical deterioration based on occlusion or ste-
nosis, or stent collapse.
Clinical improvement was deﬁned as a hemodynamic
improvement with and increase of at least 0.10 in ABI,
combined with a symptomatic improvement of at least one
Rutherford category. Re-stenosis was deﬁned as a lesion
with a peak systolic value (PSV) ratio 2.5 as measured in
the endograft and proximal or distal to the endograft or an
angiographic diameter reduction of >50%.18,19
Limb salvage rate was deﬁned as all patients without
above ankle amputations. Minor complications were
deﬁned as those that were only temporary leading to
impairment, whereas major complications were deﬁned by
permanent damage or death.Statistical analysis
Variables were expressed as mean  one standard devia-
tion (SD) in case of normal distribution, or median plus
range in other distributions. In all patients the mean ABI of
both legs was calculated to compare pre- and post-
procedural ABI with paired t tests.
Patency and limb salvage rates were estimated using
the Kaplan-Meier survival analysis on a per patient basis.
To test for survival differences, analyses with the log-rank
(Mantel-Cox), or the generalized Wilcoxon (Breslow) tests
were used. Probability values given are based on twosided analyses of test results. A signiﬁcance level of 5%
was used. Statistical analysis was performed with SPSS
version 19.0 (Statistical Package for the Social Sciences,
Inc., Chicago, IL).
RESULTS
One hundred and three patients (51 male, 52 female) un-
derwent a CERAB procedure for chronic ischemia during the
study period and were included in this study. Five other
patients were treated with a CERAB conﬁguration for acute
ischemia in this period but were excluded from this analysis,
as were ﬁve patients who were treated with chimney grafts
in the inferior mesenteric artery or renal artery in combi-
nation with a CERAB. During the study period 32 other
patients were treated with a surgical bifurcation prosthesis.
The median age of the study group was 61 years (range 36e
85 years). Patient characteristics and co-morbidities are
listed in Table 1.
The indication for treatment was disabling claudication in
64 patients (62.1%) and critical limb ischemia in 38 patients
(36.9%) (Table 1). One patient was classiﬁed as Rutherford
Category 1. He was treated for an aorto-bi-femoral bypass
at risk for occlusion because of subtotal stenosis at the
proximal anastomosis of this bypass. The median follow up
was 12 months (range 0e49 months). There was no 30 day
mortality, but eight patients died during follow up. Six pa-
tients died as a result of non-procedure related causes
(Table 2), and in the other two patients the cause of death
was unknown. Duplex follow up at 6 months was available
for 74 patients, at 1 year for 52 patients, and at 2 years for
29 patients.
In 69 patients (67.0%) this was the ﬁrst procedure
performed in the aortoiliac segment, 26 patients (25.2%)
had previously undergone endovascular procedures in this
segment, including stent placements in 17 patients. Eight
Table 1. Patient characteristics of patients treated with CERAB.
N %
Rutherford Category for chronic ischemia16:
1 mild intermittent claudication, walking
distance unlimited
1 1.0
2 moderate claudication, walking distance
>200 m
0 0
3 severe claudication, walking distance
<200 m
64 62.1
4 ischemic rest pain 20 19.4
5 focal tissue loss 17 16.5
6 diffuse gangrene 1 1.0
ASA score
1 0 0
2 69 67.0
3 27 26.2
4 7 6.8
Tobacco use
Never, >10 years ago 11 10.7
No, but <10 years ago 12 11.7
Yes < 20/day 45 43.7
Yes > 20/day 32 31.1
Unknown 3 2.9
Diabetes mellitus
No 71 68.9
Adult, dietary or oral medication controlled 15 14.6
Adult, insulin dependent 14 13.6
Juvenile diabetes 0 0
Unknown 3 2.9
Hypertension
No 22 21.4
Treated by single drug 37 35.9
Treated by two drugs 30 29.1
Treated by three drugs 11 10.7
Unknown 3 2.9
Hyperlipidemia
Normal lipids 3 2.9
Mildly elevated, dietary control 12 11.7
Treated with drugs 79 76.7
Unknown 9 8.7
Cardiac disease
Asymptomatic 58 56.3
Non-recent myocardial infarction (MI) (>6 mo)
asymptomatic MI on EKG (electrocardiogram)
26 25.2
Stable angina pectoris, arrhythmias, treatable
heart failure
10 9.7
Unstable angina pectoris, recent MI (<6 mo) 7 6.8
Unknown 2 1.9
Pulmonary disease
Asymptomatic 57 55.3
Mild dyspnea 25 24.3
Moderate dyspnea 21 20.4
O2 dependent, pulmonary hypertension 0 0
Carotid disease
No disease 84 81.6
Asymptomatic, but sign of disease 13 12.6
TIA/stroke without temporary deﬁcit 3 2.9
TIA/stroke with permanent deﬁcit 2 1.9
Unknown 1 1.0
Renal disease
No 84 81.6
GFR 30e50 mL/min 15 14.6
Table 1-continued
N %
GFR 15e30 mL/min 1 1.0
GFR < 15 mL/min or renal transplant 2 1.9
Unknown 1 1.0
ASA ¼ American Society of Anesthesiologists physical status
classiﬁcation system; GFR ¼ glomerular ﬁltration rate;
mo ¼ months; TIA ¼ transient ischemic attack.
First Results of the CERAB Technique 641patients (7.8%) had earlier surgical reconstructions,
including four aorto-bi-iliac bypasses and two aorto-bi-
femoral bypasses. The lesion characteristics are shown
in Table 3. Most patients were treated for TASC-II D
lesions.Procedural outcome
Technical success was achieved in 98 patients (95.1%).
Reasons for technical failure included three cases in which
the guidewire could not be passed because of heavily
calciﬁed lesions, in one procedure the guidewire could be
advanced, but the sheath could not pass the lesion and in
one case re-entry into the lumen could not be achieved. In
two of these patients a surgical bypass was constructed by
means of an aorto-bi-iliac bypass and an ilio-femoral
crossover bypass. In another patient, a second attempt
was successfully performed (with growing experience) 2
years after the ﬁrst procedure. The fourth patient, suffering
from focal tissue loss, died 48 days after the attempt and
before a secondary treatment could be performed.
Seventy-seven procedures (74.0%) were performed
percutaneously, and 27 (26.0%) were performed by surgical
cut down (18 one site, 9 both sites). In 21 of them the
procedure was combined with an endarterectomy of the
common femoral artery and/or distal external iliac artery. In
ﬁve patients an additional PTA was performed in the
external iliac arteries, in one patient followed by stent
placement. In one case thrombectomy of an occluded limb
of a bi-femoral bypass was performed. In one patient the
femoral artery occluded during the procedure, with reso-
lution after thrombectomy.
In 60.6% the CERAB conﬁguration consisted of a 12 mm
aortic stent either 61 mm (N ¼ 22) or 41 mm (N ¼ 38) in
length and two 8  59 mm iliac stents. In 65.7% of the
successful procedures the CERAB was completed with the
use of three covered stents, as the technique was initiallyTable 2. Cause of death during follow up of patients treated with
CERAB.
Pulmonary N ¼ 1 36 days after procedure
Cardiac N ¼ 2 48 and 62 days, respectively
after procedure
Malignancy N ¼ 2 235 and 286 days, respectively
after procedure
Bowel ischemia N ¼ 1 125 days after procedure
Unknown N ¼ 2 35 and 113 days, respectively
after procedure
642 F.A.B. Grimme et al.described. The remainder required distal extensions to
cover the entire diseased segment. Stent speciﬁcations are
listed in Table 3.
Procedural complications included 10 dissections, of
which six were treated with balloon angioplasty alone and
three with an additional stent. One dissection was left un-
treated as it was not ﬂow limiting (Table 4). There were two
iliac artery ruptures. One was covered by CERAB itself and
the other with a self expanding covered stent. In one case,
already mentioned above, thrombus formation occurred for
which a thrombectomy was performed. In two early cases a
stent dislodged from the balloon. In one the dislodged stent
was placed in the external iliac artery and in the other it
was used as an additional proximal stent in the aorta. The
overall procedural complication rate was 14.6%. AllTable 3. Lesion characteristics and stent speciﬁcations of patients
treated with CERAB.
TASC-II*
B 6 (5.8%)
C 9 (8.7%)
D 88 (85.4%)
Outﬂow vessels Right Left
External iliac
artery
Open; with stenosis;
occluded
66;27;8 73;23;5
Internal iliac
artery
Open; with stenosis;
occluded
61;26;14 59;26;16
Superﬁcial
femoral artery
Open; with stenosis;
occluded
67;31;3 70;28;3
Deep
femoral artery
Open; with stenosis;
occluded
90;11;0 92;9;0
Aortic stent length (mm)
29 5 (5.1%)
38 1 (1.0%)
41 64 (64.6%)
61 28 (28.2%)
Unknown 1 (1.0%)
Aortic stent diameter (mm)
8 1 (1.0%)
12 95 (96.0%)
14 2 (2.0%)
16 1 (1.0%)
Right Left
Iliac artery stent length (mm)
38 17 (17.1%) 14 (14.1%)
41 1 (1.0%) 2 (2.0%)
59 80 (80.1%) 83 (83.8%)
61 1 (1.0%) 0
Iliac artery stent diameter (mm)
6 4 (4.0%) 5 (5.1%)
7 2 (2.0%) 3 (3.0%)
8 88 (88.9%) 85 (85.9%)
9 1 (1.0%) 2 (2.0%)
10 3 (3.0%) 3 (3.0%)
12 1 (1.0%) 1 (1.0%)
Number of stents used
3 65 (65.7%)
4 19 (19.2%)
5 15 (15.2%)
TASC-II ¼ Classiﬁcation of Inter-Society Consensus for the
Management of Peripheral Arterial Disease (TASC II).complications, except the surgical thrombectomy, were
resolved endovascularly and did not lead to any permanent
deﬁcit.
In three patients a patent internal iliac artery was
intentionally occluded to treat concurrent occlusive disease
of the external iliac artery. In two patients the contralateral
internal iliac artery remained patent and in the third patient
it was already occluded.Clinical outcome
Thirty day post procedural complications are listed in
Table 4. There were 22 minor complications and two major
complications. Minor complications included 16 groin he-
matomas, which were left untreated. There were two
pseudo-aneurysms treated with thrombin injection and
compression bandage, respectively. There was one re-
bleeding which was conservatively treated with a
compression bandage. One patient developed atrial ﬁbril-
lation treated medically. During the post-operative course
two patients developed fever of unknown origin and both
were treated with antibiotics. Major complications
included one patient with deterioration of chronic renal
insufﬁciency after the procedure. The calculated glomer-
ular ﬁltration rate decreased from 53 to 36 mL/min/
1.73 m2. Eventually, this patient required permanent dial-
ysis 1 year after the procedure. One patient developed a
bilateral pneumonia and died 5 weeks after the procedure.
The 30 day overall complication rate was 23.3%, the major
complication rate was 1.9%, and the 30 day mortality was
0%.Table 4. Complications during CERAB procedure and during ﬁrst 30
post-procedural days.
Procedural N Severity
Dissection 10 Treated in same procedure,
not leading to impairment
Rupture/bleeding 2 Treated in same procedure,
not leading to impairment
Dislocation stent 2 Treated in same procedure,
not leading to impairment
Thrombus formation 1 Treated in same procedure,
not leading to impairment
Post-procedural (30 days)
Minor complications
Groin hematoma 16 No inﬂuence on health, one
patient temporary impaired
Re-bleed 1 Temporary impairment,
no intervention
False aneurysm 2 One recovered after
intervention, other patient
temporary impaired
Fever unknown cause 2 Temporary impairment
Atrial ﬁbrillation 1 Temporary impairment
Major complications
Kidney failure 1 Permanent damage
Pneumonia 1 Leading to death at the 36th
post-procedural day
Figure 2. Kaplan-Meier survival analysis showing patency curves of patients treated with CERAB.
First Results of the CERAB Technique 643Median duration of admission was 2 days (range 1e16
days). Twenty-one patients (20.3%) were admitted to an
intensive care unit for the median duration of 1 day (range
1e3 days).
The mean ABI, measured bilaterally, signiﬁcantly
improved from 0.64  0.21 before the procedure to
0.91  0.14 after the procedure (p < .001). The highest
measured ABI before the procedure improved from
0.71  0.25 to 0.93  0.14 after the procedure, measured
using the same leg. Clinical improvement with at least one
Rutherford category occurred in 89 of 96 patients (92.7%) at
6 months after the procedure. In the remaining threepatients with technically successful CERAB no post-
procedural Rutherford category was documented. The pa-
tients who did not improve included the patient with
Rutherford 1, who was treated for a bypass at risk. One
patient had no improvement because of a persistent
dissection distal to the additional stent which was placed
during the procedure. She was treated by further stent
placement, 3 months after the CERAB procedure. Two pa-
tients had a stent collapse/severe kinking of one of the iliac
stents at day 21 and day 30, respectively. One patient un-
derwent kissing balloon PTA and the other patient con-
verted to an aortic-bi-iliac surgical bypass as the patient
644 F.A.B. Grimme et al.refused further endovascular treatment. One patient did
not improve because of a short occlusion of the common
femoral artery for which an endarterectomy was performed
5 months after the CERAB procedure. Another patient did
not improve because of multiple stenoses in the superﬁcial
femoral artery for which balloon angioplasty was per-
formed. In one patient, treated for severe claudication, the
CERAB was extended to the external iliac artery for a ste-
nosis distal to the stent after a month, without clinical
improvement. The patient died before another re-
intervention could be performed.
Patency rates
The primary patency rate at 6 months was 90.2%, at 1 year
87.3%, and at 2 years 82.3% (Fig. 2). At 6 months theFigure 3. Kaplan-Meier survival analysis showing primary patency curv
previous intervention.secondary patency rate was 96.5%, 95.0% at 1 year, and
95.0% at 2 years (Fig. 2). Freedom from TLR was 92.4% at 6
months, 88.2% after 1 year, and 85.6% at 2 years (Fig. 2).
Univariate analysis showed no signiﬁcant inﬂuence of
smoking, diabetes mellitus, hypertension, dyslipidemia,
renal disease, coronary artery disease, or carotid disease on
the primary patency rates. There was no difference in the
primary patency between patients treated for critical limb
ischemia or intermittent claudication (p ¼ .90). There was
also no signiﬁcant difference between patients who were
primarily treated with CERAB and those who underwent
previous intervention (p ¼ .44) (Fig. 3). There were no
differences in primary patency rate between the ﬁrst 20
patients treated in each clinic, compared with the patients
treated thereafter (p ¼ .33).es of patients primarily treated with CERAB or CERAB following a
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during follow up. Ten patients had re-stenosis, of which
three were caused by kinking of one of the iliac stents or
stent collapse. These patients were treated by PTA and in
one case by additional stent placement. The other seven
patients developed a stenosis above the aortic stent (N ¼ 1)
or distal to the iliac stents (N ¼ 6), referred to as edge
stenosis. Two cases were not treated as the patients were
symptom free, in three cases the iliac limb was extended
with an additional CBES, and in the other two cases a PTA
was performed. Five CERABs occluded, of which, one
occurred after the patient stopped the anti-platelets. In two
patients, treated with surgical thrombectomy and ﬁbrino-
lysis, respectively, an outﬂow stenosis was found in the
external iliac artery and treated by PTA in one case and an
extra CBES in the other. In one patient there was a stent
collapse of one of the iliac CBES. No cause was identiﬁed for
the occlusion in the last patient. The latter two were treated
with a surgical bypass. Loss of primary patency occurred in
nine patients within the ﬁrst 6 months of the procedure and
in two patients after 2 years. The limb salvage rate was
100%.DISCUSSION
In this study the ﬁrst results of the CERAB technique are
presented, which conﬁrm the safety and efﬁcacy of this new
endovascular approach for extensive and complex occlusive
lesions of the aortic bifurcation. To date, surgical recon-
struction has been the gold standard for the treatment of
TASC-II C and D lesions according to the TASC-II guidelines.1
By mimicking the aortic bifurcation anatomically and
physiologically, CERAB might improve the patency rate of
endovascular techniques and also reduce the risk of severe
complications when compared with surgical reconstruction.
The technique may be a valid alternative to current treat-
ment modalities.
Calculated primary patency rates of the CERAB procedure
in this study cohort are 87.3% at 1 year and 82.3% at 2
years. These primary patency rates appear to be at the same
level as have been described for kissing stents. However,
many patients in the present study, in contrast with the
kissing stent series, were treated for the more complex
TASC-II D lesions. The published kissing stent series usually
consist of mixed populations treated for all TASC lesions and
treated for different indications. In a recent review, it was
shown that the indications for treatment with kissing stents
varied greatly, from 33% to 100% of patients treated for
claudication.20 In the present study 36.9% of the patients
were treated for critical limb ischemia. In addition, the
incidence of TASC A and B lesions treated with kissing stents
varied from 0% to 92%, rendering comparisons unfair with
the present group of patients, who were mostly treated for
TASC-II D lesions. Another point of interest is the deﬁnition
of loss of primary patency used. This study used a deﬁnition
that included re-stenosis, as was also used by Sabri et al. in
their historical cohort study on kissing covered stents.8 This
is in contrast with the outcomes presented by Humphrieset al., where primary patency was only affected by stent
occlusion or re-interventions.21 In the present authors’
opinion, re-stenosis is an important outcome of endovas-
cular procedures and should be taken into account, as
Diehm et al. have suggested.18
Re-interventions performed to improve or preserve
outﬂow will decrease primary patency rates. As two pa-
tients developed occlusions based on outﬂow impairment,
the present authors advocate treatment of stenosis in the
iliac tract aggressively to prevent occlusions. This may lead
to an increased incidence of re-interventions, even in the
absence of symptoms. Secondary patency rates were
excellent, 95.0% at 2 years. This implies greater durability of
CERAB when preventive re-interventions are performed. In
examining re-interventions performed for clinical symptoms
(e.g. freedom from TLR), patency rates were 88.2% at 1 year
and 85.6% at 2 years.
Loss of primary patency was affected by three major
causes. The ﬁrst and most important reason was stenosis
resulting in outﬂow obstruction. This emphasizes that it is
essential to cover the entire stenotic area, with special
attention to the distal end before deployment. Otherwise
the atherosclerotic lesion may advance distally, resulting in
an edge stenosis. The present authors advocate covering
the disease from healthy to healthy areas, although intimal
disease will always be present in atherosclerosis. Second,
four cases of stent collapse or kinking of the iliac tract were
observed. In three cases the collapse was situated at the
point of crossing of the iliac stents, at the level of the cuff of
the aortic stent, thereby pointing at a weakness of the
present technique. Another collapse occurred in a 6 mm
stent distal to the aortic cuff, at the origin of the native iliac
artery. It is possible that highly calciﬁed lesions overcome
the radial force of the CBES, especially in small diameters,
and improvement in stent design could be used to solve this
problem. One patient had an occlusion possibly related to
poor therapy compliance. This underlines the importance of
the use of anti-platelet or anti-coagulation therapy. In the
present study protocol, all patients were treated with anti-
platelet therapy, including clopidogrel during the ﬁrst 6
months and lifelong acetyl salicylic acid (with the exception
of patients treated with anti-coagulants such as acenocou-
marol or warfarin for other indications). In a high ﬂow
reconstruction, however, single anti-platelet therapy might
be adequate, but no scientiﬁc argument is provided for this
in this ﬁrst case series.
In the present study all patients were included from
February 2009 to March 2014. As patency curves did not
differ signiﬁcantly after the treatment of 20 patients, a
learning curve was not found to be a factor that affected
the results. One would expect that with growing experience
results would improve, however, with growing experience
the indication for CERAB was expanded in both hospitals to
patients with more and more complex lesions, which could
possibly have affected results negatively, thereby hiding a
learning curve effect. The effect of experience is shown in a
patient who underwent a successful CERAB procedure, 2
years after an initial failure. In both clinics, an endovascular
646 F.A.B. Grimme et al.ﬁrst strategy is now applied and surgical bypass grafting is
reserved for those patients in whom a CERAB cannot be
performed. Now, no patients are excluded for CERAB based
on pre-operative imaging. Nevertheless, in very complex
lesions in low risk patients, open surgery is always consid-
ered. The kissing stent technique has mostly been
abandoned.
When treating an occlusion it may be difﬁcult to deter-
mine whether the guidewire is advanced intraluminally or
subintimally, but as the entire lesion is covered with CBES,
this is not clinically relevant. Re-entry to the vascular lumen
is always made as distal as possible in the patent aorta.
When renal arteries or even visceral arteries are involved in
the diseased segment, the use of protective balloons or
chimney grafts may be considered.
One of the advantages of the use of CBES is that it might
prevent or immediately treat procedural complications such
as rupture and distal embolization. There were no clinical
signs of distal embolization in the present series. The two
ruptures that occurred during procedure were both treated
endovascularly, one with the CERAB itself. Other complica-
tions during the procedure could all be treated endovasc-
ularly, without clinical consequences for the patient making
the procedure extremely safe. Patent lumbar collaterals
may be occluded by the covered stents, but in the present
cohort no patients had symptoms of spinal cord ischemia.
Two major complications occurred for a major compli-
cation rate of 1.9%. In one patient, pre-operative impaired
renal function worsened after treatment, ultimately leading
to hemodialysis after 1 year. This underlines the importance
of peri-operative measures to reduce the risk of contrast
induced nephropathy. The other major complication con-
sisted of a bilateral pneumonia. This patient was admitted
from the department of cardiology and was deemed unﬁt
for a surgical bypass procedure because of cardiac and
pulmonary comorbidity. After 3 days of post-procedural
observation in the ICU, he was re-admitted to the depart-
ment of cardiology where he developed a bilateral pneu-
monia. Eventually the patient died 5 weeks after the
procedure. This demonstrates the vulnerability of this group
of patients. Most of the observed complications in the
present cohort were minor hematomas in the groin. In
cases of percutaneous access two types of closure devices
were used, but the signiﬁcance of this cannot be assessed
as it was not in the scope of the present study. The close
observation of the present population treated with a new
technique, also reﬂected by the high ICU admission in the
early experience, may explain the relatively high incidence
of hematomas. Overall, CERAB seems to be associated with
a lower major morbidity rate compared with surgical
reconstruction, but this should to be established in a ran-
domized trial.
CBES are more expensive than bare metal stents and
therefore the cost-effectiveness of the CERAB procedure is
unclear and needs to be addressed. The need for re-
interventions may even increase costs in the long term.
However, the low morbidity and mortality compared with
surgical repair also reduces costs with regard to in hospitaland ICU stay. Moreover, the long-term morbidity of surgical
repair, including incisional hernia and adhesion formation
with the risk of small bowel obstruction, is accompanied by
high costs as well, but these are often neglected. With
CERAB the in hospital stay is short with a median hospital
stay of 2 days. The ﬁrst patients treated were observed
post-operatively in the ICU according to the protocol of
aortic bifurcation reconstructions. Meanwhile, the protocol
has changed for endovascular reconstructions. Therefore,
the 20.3% ICU admission appears to be a large over-
estimation of the need for close hemodynamic observation.
Observation at a so called medium care facility could pro-
vide an alternative; however, one of the hospitals included
in this study does not have such a unit. From the last 60
patients treated, only nine were observed in the ICU, for
cardiac or pulmonary reasons. Given the low morbidity rate,
treatment on an outpatient basis could be justiﬁed. It may
be possible to abandon the annual duplex ultrasound when
the technique has proved its safety in the long term.
This study is limited by being retrospective, therefore the
results are likely to be affected by selection bias. Some data
are lacking, such as the occurrence of symptoms of buttock
claudication or erectile dysfunction after the procedure,
which could not reliably be retrieved from the databases.
Furthermore, follow up of 2 years was not completed for
the entire cohort. The standard error of estimated patency
rates at 2 years was 4.9%, conﬁrming the reliability of the
calculated patency rates. This study presents the ﬁrst world
experience with the CERAB technique, and long-term data
are required before the technique can be considered the
new standard.
A randomized controlled trial with prolonged follow up to
compare surgical bypass procedures, the kissing stent
technique, and CERAB for TASC-II D lesions is indicated to
compare morbidity, outcome, and cost-effectiveness. The
feasibility of such a study is low however, because of the
relatively low incidence of these lesions and as the co-
morbidity in many patients could drive the physicians to-
wards an endovascular preference, to reduce morbidity and
mortality.CONCLUSION
The CERAB technique is a safe and feasible alternative to
open surgical reconstruction of the aortic bifurcation in
complex AIOD. Comparative studies with the current gold
standards are indicated to deﬁne the role of this technique
in the treatment algorithm of TASC-II C and D lesions.
Critical issues include long-term patency rates, cost-
effectiveness, patient selection, ﬁne tuning of the tech-
nique, and deﬁnition of optimal medical support.CONFLICT OF INTEREST
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